Published on 24/12/2025

SPL validation and testing requirements in 2023

Structured Product Labeling (SPL) is a standard for the representation of product information that allows for the consistent management of regulatory submissions throughout the lifecycle of drugs, biological products, and medical devices. With the advent of digital transformation in regulatory affairs, understanding the validation and testing requirements for SPL is crucial for compliance professionals in the US, UK, and EU. This article serves as a step-by-step guide to help regulatory affairs professionals navigate SPL regulatory compliance consulting services while ensuring adherence to the relevant requirements in 2023.

Understanding SPL and Its Regulatory Landscape

Structured Product Labeling (SPL) is rooted in the need for a standard format to convey product information to stakeholders and regulators effectively. SPL is defined under FDA regulations and widely adopted by other regulatory agencies such as the EMA and MHRA. The implementation of SPL facilitates a streamlined approach to submitting product data. As we proceed into 2023, the regulatory landscape surrounding SPL is continuously evolving, influenced by the integration of International Drug Model (IDMP), Sustained Product Object Reference (SPOR), International Organization for Standardization (ISO) standards, and regulatory information management (RIM) systems.

The current SPL framework serves as a vital roadmap for regulatory affairs professionals, guiding the submission of both product labeling and clinical data. Understanding how to validate and test SPL submissions is paramount in ensuring regulatory compliance. Failure to comply with these regulations can lead to delays in the submission process, fines, and restrictions on market access.

The goal of this section is to establish a foundational understanding of SPL compliance requirements, emphasizing the importance of following guidelines set forth by the FDA, EMA, and MHRA.

Step 1: Establish Your SPL Compliance Framework

To initiate the SPL validation process, organizations must first develop a robust compliance framework. This framework should clearly delineate the roles and responsibilities of the personnel involved, along with a timeline outlining the steps for SPL validation. Below are key considerations for establishing the compliance framework:

• Define Roles: Assign specific roles to team members across regulatory, IT, and quality assurance departments. Ensure that everyone understands their responsibilities regarding SPL submissions.
• Documentation: Create a comprehensive documentation plan that includes all relevant SPL-related documents, validation methodologies, and compliance protocols. This may involve creating a standard operating procedure (SOP).
• Training: Conduct training sessions for team members involved in SPL submissions to ensure familiarity with the evolving regulatory standards and the SPL format.
• Project Timeline: Establish realistic timelines for each phase of the SPL validation process. Clearly mark milestones for document submission, review cycles, and final approvals.

This foundational step fortifies the groundwork for a successful SPL validation and testing process, facilitating collaboration across departments while enhancing regulatory compliance.

Step 2: Understand the SPL Technical Standards

Compliance with technical standards is essential for successful SPL submissions. Familiarizing yourself with the latest technical specifications mandated by regulatory authorities is critical. In 2023, the focus on aligning SPL submissions with IDMP and SPOR standards has grown significantly. These standards emphasize consistency, accuracy, and traceability of product information.

Regulatory agencies have established various technical characteristics that SPL must meet, including:

• XML Format: SPL submissions must conform to the XML-based structure defined by the FDA and other authorities. This entails proper tagging and organization of product information.
• Data Elements: Each SPL submission must incorporate specific data elements per regulatory requirements, such as product identification, labeling claims, and usage instructions.
• Version Control: Ensure that SPL submissions are version-controlled to avoid discrepancies and allow for effective audit trails.
• Validation Rules: Understand specific validation rules that govern the SPL format, which can include rules for data integrity and format adherence.

The importance of adopting these technical standards cannot be understated. Non-compliance can lead to rejection of SPL submissions, resulting in costly delays. Therefore, staying current with updates and revisions from regulatory authorities fosters adherence to these standards.

Step 3: Conduct Preliminary SPL Testing

After establishing a compliance framework and understanding the technical standards, organizations should conduct preliminary testing of their SPL data. This testing phase ensures that the SPL meets all the specified requirements before formal submission. The preliminary testing should comprise:

• Internal Validation: Develop internal validation checks to ascertain the alignment of SPL data with regulatory standards. This includes random checks of XML formatting, completeness of required data elements, and accuracy of product information.
• Automated Testing: Leverage automated validation tools to evaluate SPL submissions against predefined standards. This method is efficient and can reduce the risk of human error.
• Stakeholder Review: Involve key stakeholders in reviewing preliminary SPL submissions. This collaborative effort provides insights and can reveal potential areas of concern.

Identifying and resolving issues at this stage enhances the likelihood of successful SPL submission and minimizes the risk of delays. Keeping detailed records of the testing results is crucial for transparency and compliance.

Step 4: Engage in External Validation and Testing

Following preliminary testing, organizations should consider engaging external validation resources, particularly when dealing with complex SPL submissions. External Validator Consultations ensure an unbiased review of the SPL data and adherence to regulatory compliance. This step should involve:

• Consultation with SPL Experts: Engage with regulatory compliance consulting services specializing in SPL to conduct objective reviews of your submissions. These experts often have specific experience navigating the complexities of SPL requirements.
• Benchmarking Against Industry Standards: Use external resources to compare SPL submissions against industry benchmarks to gauge compliance and identify potential areas for enhancement.
• Incorporating Feedback: Use insights gathered from external validation to update and refine SPL submissions before final submission to regulatory authorities.

Utilizing third-party expertise can enhance the quality and compliance of SPL submissions. Additionally, external validation can serve as a safeguard against potential regulatory pitfalls.

Step 5: Final SPL Submission and Reporting

The final SPL submission is a critical phase in the regulatory compliance process. In this step, organizations take the validated SPL and submit it to the designated regulatory authorities. Important considerations during this phase include:

• Organizing Submission Packages: Ensure that all required supporting documents accompany the SPL submission. This may include clinical data, manufacturing information, and labeling content.
• Communication with Regulatory Authorities: Maintain open lines of communication with regulatory authorities during the submission process. This can help clarify any ambiguities or requirements that may arise.
• Record Keeping: Keep detailed records of submissions, including date stamps, confirmation receipts, and any correspondence with regulatory agencies. This is crucial for compliance and future audits.

Once the SPL submission is made, organizations must remain prepared for possible follow-up from regulators. This may include additional queries or requests for data clarification. Addressing these promptly can facilitate efficient approvals.

Step 6: Post-Submission Review and Continuous Improvement

After the SPL submission is approved, organizations should implement a post-submission review process. This aims to identify lessons learned and establish protocols for continuous improvement in SPL compliance. Key aspects to consider include:

• Lessons Learned Documentation: Document all insights gained during the validation, testing, and submission process to enhance future SPL submissions.
• Feedback Mechanisms: Develop feedback mechanisms to gather input from stakeholders and team members to refine processes.
• Regulatory Updates: Stay abreast of changes in regulatory requirements concerning SPL. Continuous engagement with agencies such as the FDA, EMA, and MHRA will ensure that organizations remain compliant.

Employing a culture of continuous improvement not only enhances compliance but also fosters operational efficiency. Regulatory affairs professionals should advocate for periodic reviews and updated training programs to ensure that teams remain current with regulatory developments.

Conclusion: Ensuring SPL Regulatory Compliance

In conclusion, ensuring compliance with SPL submission requirements is a multifaceted process that encompasses a thorough understanding of regulatory frameworks, adherence to technical standards, and continuous engagement with both internal and external stakeholders. Regulatory affairs professionals must focus on developing a comprehensive strategy for SPL validation and testing that adapts to the changing landscapes of FDA, EMA, and MHRA regulations.

By following the steps outlined in this guide, organizations can effectively navigate the complexities associated with SPL regulatory compliance consulting services. The need for streamlined regulatory digital transformations through structured product labeling cannot be overstated. Maintaining compliance not only facilitates smoother product approvals but ultimately enhances patient safety and contributes to public health.

For further guidance, regulatory professionals are encouraged to refer to resources from the World Health Organization (WHO), the FDA, and the EMA for the latest updates regarding SPL validation and testing requirements.